INTEGRAL MOLECULAR INC — Department of Health and Human Services SBIR Phase I: 300
INTEGRAL MOLECULAR INC — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $471,745
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- 300
- Solicitation
- PA11-335
- NAICS
- —
- Place of performance
- PA
- Period
- 2014-09-05 → 2016-05-31
Description
DESCRIPTION provided by applicant Ion channels such as Kv and Nav are involved in a number of human disorders including autoimmunity and pain that affect andgt million Americans annually and are poorly treated However ion channels are typically exceptionally difficult to express at high levels due to their structural complexity and toxicity s a result many research and therapeutic applications for these targets have been very limited where high levels of membrane protein are required For example for human voltage gated potassium Kv and sodium Nav ion channels there are no solved crystal structures and no therapeutic monoclonal antibodies MAbs approved by the FDA or even in clinical trials despite the high level of pharmaceutical interest in such MAbs as therapeutics These applications all typically require high levels of protein expression and the expression of most ion channels is usually orders of magnitude below what is required for success Here we propose to develop a versatile platform for expressing high levels of conformational ion channel proteins Our use of this platform within the scope of this proposal will be for isolating unique MAbs against Kv and Nav We expect that this platform will be extensible to other ion channels and will also have utility for structural research high throughput screening and as biomedical research reagents PUBLIC HEALTH RELEVANCE This proposal will contribute to human health and the cure of human disease through the development of a platform for high expressing ion channels that can be used for research and therapeutic applications Our own use of this platform within the scope of this proposal will be for isolating unique MAbs that can be developed into human therapeutics to treat pain and auto immune disorders conditions that affect andgt million Americans each year and that currently have poor treatments We expect that this platform will also have utility for structural research high throughput screening and as biomedical research reagents